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Epstein Barr Virus Associated Posttransplant LYmphO~~Ii~r~e 
Disease After Intestinal Transplantation 
J. Reyes, M. Green, J. Bueno, N. Jabbour, M. Nalesnik, E. Yunis, S. Kocoshis, M. Kauffman, S. Todo, 
and T.E. Starzl 
PREVIOUS reports of posttransplant lymphoprolifera-
tive disease (PTLD) after intestinal transplantation 
described a high incidence with consequent significant 
morbidity and mortality. 1 We present the clinicaVpatholog-
ical spectrum of PTLD occurring after intestinal transplan-
tation with particular emphasis on risk factors and effect on 
patient and graft survival. 
MATERIALS AND METHODS 
Case Material 
Between May 1990 and June 1995, 73 patients received 78 intesti-
nal transplants under tacrolimus and steroid immunosuppression. 
These included the following grafts: small bowel (SB) (n = 28), 
liver/small bowel (LSB) (n = 35), and multivisceral (MV) (n = 15) 
recipients. There were 41 children and 32 adults transplanted; their 
ages ranged between 0.5 and 58.1 years. Immunosuppression, 
donor. and recipient surgical procedures, and nutritional manage-
ment have been described elsewhere." 
Pathological Studies 
All available surgical and autopsy specimens were reviewed. The 
evaluation of PTLD lesions included histopathology, analysis of 
clonal status. and demonstration of EBV (by in-situ hybridization 
[EBERl). PTLD was defined as the presence of lymphoid growths 
from any site after transplantation. These lymphoid growths may 
present as tumor. destructive infiltrates. with or without clonal 
proliferations. and show EBER positivity. Recipient EBV serology 
was obtained preoperatively. 
RESULTS 
Patient Population and Tumor Incidence 
Fourteen cases (19%) of PTLD were identified. The overall 
incidence in the adult and pediatric recipients was 9.3% and 
26.8%. respectively. Seven occurred in males and 7 oc-
curred in females (male/female ratio 1/1). Eleven patients 
were children with a median age of 2.8 years. The time 
between the date of organ transplant and the date of 
disease presentation ranged between 24 days to 5 years 
(median time of 9 months). 
The recurrence of PTLD at retransplantation produced 
16 cases which were distributed relative to graft type as 
follows: three cases after SB (10.77<). seven cases after LSB 
graft (20%). and 6 cases after MV grafts (40%). There were 
a tot a I of 18 episodes of PTLD among these 14 recipicnts 
(recurrence rate of 28.5%). Persistent. intractahle diseuse 
was seen in four patients. with eventual dcuth in three. 
Pathological Features of PTLD 
The range of histology was that of lymphocytic infiltrates 
with a monomorphic and/or polymorphic appearance. Plas-
macytoid features were seen in the chronic cases. Depend-
ing on the stage of the PTLD, there was some admixture of 
immunoblastic cells as well as eosinophils and polymorpho-
nuclear cells. Reed-Sternberg-like cells were seen in only 
three cases in a setting of very atypical lymphocytes and 
immunoblastic cells, with necrosis. Two patients presented 
a unique spindle cell tumor (of smooth muscle origin) in the 
native and allograft intestine as previously reported.3 
Clonal analysis was performed in nine patients: the lesions 
were monoclonal in seven patients and polyc1onal in two. 
Evidence of EBER positivity was seen in all cases. Serologic 
evidence of prior EBV infection was found in 10 patients. 
The most common region of involvement was the gastro-
intestinal tract, principally allograft but also native. A 
lymphadenopathic presentation was seen in only one pa-
tient and was amenable to rapid and complete remission of 
disease with preservation of graft function. Seven of 14 
patients received OKT3. A history of splenectomy was 
noted in 12 of 14 recipients. 
Treatment of PTLD 
Therapy consisted of reduction of immunosuppression 
combined with intravenous acyclovir or ganciclovir for as 
long as the lesions were present. Alpha interferon and 
foscarnet were used in selected cases. Two of the patients 
who were placed on interferon suffered significant rejection 
episodes post-interferon therapy. In two cases the immuno-
suppression was stopped completely while there was evi-
dence of clinical disease: however. one patient suffered 
severe rejection post-withdrawal of immunosuppression 
which required augmentation of immunosuppression. Hy-
perimmuneglobulin therapy was used in four patients. 
Chemotherapy was used in one patient with fulminant 
disease. 
OUTCOME 
Seven of the 14 patients diagnosed with PTLD have sur-
vived (mortality of 50%). Only five of the surviving patients 
have had complete remission of their disease. whereas two 
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INTESTINAL TRANSPLANTATION 
patients continue to have lesions and are under therapy. 
Four of the surviving patients have retained their original 
grafts and are TPN free. Retransplantation was performed 
in two cases, with one death. A SB recipient was retrans-
planted after complete resolution of disease and has sur-
vived. He is presently off TPN. Of the seven patients who 
died, all were identified to have residual PTLD. Causes of 
death included: PTLD (n = 4), intestinal allograft rejection 
(n = 2), and iatrogenic hypematremia (n = 1). 
DISCUSSION 
The mainstay of therapy continues to be judicious reduction 
of immunosuppression with antiviral therapy. However, 
though this has been generally successful for the treatment 
of PTLD in recipients of other organs, this has not been so 
in the intestinal transplant population. Rebound intestinal 
allograft rejection has occurred early, without complete 
resolution of the PTLD disease. This has percipiated sig-
nificant morbidity as well as patient and graft loss not only 
from PTLD, but also as a result of rejection. 
The addition of hyperimmuneglobulin therapy in this 
2769 
patient population was stimulated by the use of EBV PCR, 
and its consequent decrease in one patient. However, the 
role of this type of therapy as well as the use of alpha 
interferon or foscamet remains to be determined. 
In light of the experience reported with EBV peR in this 
issue,5 it is likely that both early diagnosis added to 
immunemodulation and antiviral therapy may be successful 
in the future. PTLD was treated successfully in three 
surviving patients, who presently maintain a base line 
immunosuppression using tacrolimus and steroids. 
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